As shown in Figure 5F, AMPK-null MEFs were more resistant to metformin compared to AMPK WT MEFs, and this was also confirmed in triple negative breast cancer cells, where knockdown of AMPK decreased metformin sensitivity (Figure 5G). The gene discussed is PRKAA2; the disease is triple-negative breast carcinoma.